TY - JOUR
T1 - Outcomes after TIPS for Ascites and Variceal Bleeding in a Contemporary Era - An ALTA Group Study
AU - Advancing Liver Therapeutic Approaches (ALTA) Study Group
AU - Boike, Justin Richard
AU - Mazumder, Nikhilesh Ray
AU - Kolli, Kanti Pallav
AU - Ge, Jin
AU - German, Margarita
AU - Jest, Nathaniel
AU - Morelli, Giuseppe
AU - Spengler, Erin
AU - Said, Adnan
AU - Lai, Jennifer C.
AU - Desai, Archita P.
AU - Couri, Thomas
AU - Paul, Sonali
AU - Frenette, Catherine
AU - Verna, Elizabeth C.
AU - Rahim, Usman
AU - Goel, Aparna
AU - Gregory, Dyanna
AU - Thornburg, Bartley
AU - VanWagner, Lisa B.
N1 - Publisher Copyright:
© 2021 Wolters Kluwer Health. All rights reserved.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - INTRODUCTION:Advances in transjugular intrahepatic portosystemic shunt (TIPS) technology have led to expanded use. We sought to characterize contemporary outcomes of TIPS by common indications.METHODS:This was a multicenter, retrospective cohort study using data from the Advancing Liver Therapeutic Approaches study group among adults with cirrhosis who underwent TIPS for ascites/hepatic hydrothorax (ascites/HH) or variceal bleeding (2010-2015). Adjusted competing risk analysis was used to assess post-TIPS mortality or liver transplantation (LT).RESULTS:Among 1,129 TIPS recipients, 58% received TIPS for ascites/HH and 42% for variceal bleeding. In patients who underwent TIPS for ascites/HH, the subdistribution hazard ratio (sHR) for death was similar across all Model for End-Stage Liver Disease Sodium (MELD-Na) categories with an increasing sHR with rising MELD-Na. In patients with TIPS for variceal bleeding, MELD-Na ≥20 was associated with increased hazard for death, whereas MELD-Na ≥22 was associated with LT. In a multivariate analysis, serum creatinine was most significantly associated with death (sHR 1.2 per mg/dL, 95% confidence interval [CI] 1.04-1.4 and 1.37, 95% CI 1.08-1.73 in ascites/HH and variceal bleeding, respectively). Bilirubin and international normalized ratio were most associated with LT in ascites/HH (sHR 1.23, 95% CI 1.15-1.3; sHR 2.99, 95% CI 1.76-5.1, respectively) compared with only bilirubin in variceal bleeding (sHR 1.06, 95% CI 1.00-1.13).DISCUSSION:MELD-Na has differing relationships with patient outcomes dependent on TIPS indication. These data provide new insights into contemporary predictors of outcomes after TIPS.
AB - INTRODUCTION:Advances in transjugular intrahepatic portosystemic shunt (TIPS) technology have led to expanded use. We sought to characterize contemporary outcomes of TIPS by common indications.METHODS:This was a multicenter, retrospective cohort study using data from the Advancing Liver Therapeutic Approaches study group among adults with cirrhosis who underwent TIPS for ascites/hepatic hydrothorax (ascites/HH) or variceal bleeding (2010-2015). Adjusted competing risk analysis was used to assess post-TIPS mortality or liver transplantation (LT).RESULTS:Among 1,129 TIPS recipients, 58% received TIPS for ascites/HH and 42% for variceal bleeding. In patients who underwent TIPS for ascites/HH, the subdistribution hazard ratio (sHR) for death was similar across all Model for End-Stage Liver Disease Sodium (MELD-Na) categories with an increasing sHR with rising MELD-Na. In patients with TIPS for variceal bleeding, MELD-Na ≥20 was associated with increased hazard for death, whereas MELD-Na ≥22 was associated with LT. In a multivariate analysis, serum creatinine was most significantly associated with death (sHR 1.2 per mg/dL, 95% confidence interval [CI] 1.04-1.4 and 1.37, 95% CI 1.08-1.73 in ascites/HH and variceal bleeding, respectively). Bilirubin and international normalized ratio were most associated with LT in ascites/HH (sHR 1.23, 95% CI 1.15-1.3; sHR 2.99, 95% CI 1.76-5.1, respectively) compared with only bilirubin in variceal bleeding (sHR 1.06, 95% CI 1.00-1.13).DISCUSSION:MELD-Na has differing relationships with patient outcomes dependent on TIPS indication. These data provide new insights into contemporary predictors of outcomes after TIPS.
UR - http://www.scopus.com/inward/record.url?scp=85118283154&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118283154&partnerID=8YFLogxK
U2 - 10.14309/ajg.0000000000001357
DO - 10.14309/ajg.0000000000001357
M3 - Article
C2 - 34158464
AN - SCOPUS:85118283154
SN - 0002-9270
VL - 116
SP - 2079
EP - 2088
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 10
ER -